A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure

PHASE4

Phase

COMPLETED

Status

545

Enrollment

NETWORK

Sponsor class

Conditions

DRUG: Darunavir
DRUG: Etravirine
DRUG: Emtricitabine/tenofovir disoproxil fumarate
DRUG: Raltegravir
DRUG: Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)
DRUG: Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available
OTHER: SOC adherence versus SOC+CPI adherence

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections